BRAF mutant metastatic colorectal cancers: new arrows in our quiver

BRAF mutations occur in 8–12% of metastatic colorectal cancers (mCRC) and more than 95% of them consist in a T>A transversion in exon 15 resulting in an amino acid substitution from valine to glutamic acid (V600E) that is able to increase BRAF kinase activity by approximately 10-fold (1,2).